| Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2 |
| Xu, ZJ; Shi, DR; Han, JB; Ling, Y; Jiang, XR; Lu, XY; Li, C; Gong, LK; Ge, GB; Zhang, YN; Zang, Y; Song, TZ; Feng, XL; Tian, RR; Ji, J; Zhu, MJ; Wu, NP; Wu, CH; Wang, Z; Xu, YC; Peng, C; Zheng, M; Yang, JL; Du, FF; Wu, JL; Wang, PP; Shen, JS; Zhang, JL; Zheng, YT; Yao, HP; Zhu, WL
|
| 2023
|
| 发表期刊 | SIGNAL TRANSDUCTION AND TARGETED THERAPY
 |
| ISSN | 2095-9907
|
| 卷号 | 8期号:1 |
| 摘要 | Effective drugs with broad spectrum safety profile to all people are highly expected to combat COVID-19 caused by SARS-CoV-2. Here we report that nelfinavir, an FDA approved drug for the treatment of HIV infection, is effective against SARS-CoV-2 and COVID-19. Preincubation of nelfinavir could inhibit the activity of the main protease of the SARS-CoV-2 (IC50 = 8.26 mu M), while its antiviral activity in Vero E6 cells against a clinical isolate of SARS-CoV-2 was determined to be 2.93 mu M (EC50). In comparison with vehicle-treated animals, rhesus macaque prophylactically treated with nelfinavir had significantly lower temperature and significantly reduced virus loads in the nasal and anal swabs of the animals. At necropsy, nelfinavir-treated animals had a significant reduction of the viral replication in the lungs by nearly three orders of magnitude. A prospective clinic study with 37 enrolled treatment-naive patients at Shanghai Public Health Clinical Center, which were randomized (1:1) to nelfinavir and control groups, showed that the nelfinavir treatment could shorten the duration of viral shedding by 5.5 days (9.0 vs. 14.5 days, P = 0.055) and the duration of fever time by 3.8 days (2.8 vs. 6.6 days, P = 0.014) in mild/moderate COVID-19 patients. The antiviral efficiency and clinical benefits in rhesus macaque model and in COVID-19 patients, together with its well-established good safety profile in almost all ages and during pregnancy, indicated that nelfinavir is a highly promising medication with the potential of preventative effect for the treatment of COVID-19. |
| 收录类别 | SCI
|
| 语种 | 英语
|
| 文献类型 | 期刊论文
|
| 条目标识符 | http://ir.kiz.ac.cn/handle/152453/13980
|
| 专题 | 科研部门_分子免疫药理学（郑永唐）
|
推荐引用方式
GB/T 7714 |
Xu, ZJ,Shi, DR,Han, JB,et al. Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2[J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY,2023,8(1).
|
| APA |
Xu, ZJ.,Shi, DR.,Han, JB.,Ling, Y.,Jiang, XR.,...&Zhu, WL.(2023).Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2.SIGNAL TRANSDUCTION AND TARGETED THERAPY,8(1).
|
| MLA |
Xu, ZJ,et al."Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2".SIGNAL TRANSDUCTION AND TARGETED THERAPY 8.1(2023).
|
修改评论